Paratek has bagged its first — and second — FDA OK for its antibiotics on the same day.
The big approval, 20 years in the making, goes to omadacycline — dubbed Nuzyra — for both community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,